125742 S1 M5 5351 c4591001 fa interim protocol deviations
Document text
16.2.2.1 Listing of Important Protocol Deviations – Phase 1, 2 Doses, 21 Days Apar t
Protocol
Deviation
Category Protocol Deviation Subcategory Number
of
Subjects Subject
(Number of
Deviations if >1)
Inclusion/E xclusion Participant met exclusion criterion #19 ( Phase 1 only: any screening hematology and/or blood
chemistry laboratory value that meets the definition of a >=grade 1 abnormality) 1 C4591001 1002
10021053
Inclusion/Exclusion Participant met exclusion criterion #19 ( Phase 1 only: any screening hematology and/or blood
chemistry laboratory value that meets the definition of a >=grade 1 abnormality) 1 C4591001 1003
10031021
Inclusion/Exclusion Participant met exclusion criterion #19 ( Phase 1 only: any screening hematology and/or blood
chemistry laboratory value that meets the definition of a >=grade 1 abnormality) 1 C4591001 1003
10031047
Inclusion/Exclusion Participant met exclusion criterion #19 ( Phase 1 only: any screening hematology and/or blood
chemistry laboratory value that meets the definition of a >=grade 1 abnormality) 2 C4591001 1003
10031017
C4591001 1003
10031070
PFIZER CONFIDENTIAL SDTM Creation: 28AUG2020 (16:27) Source Data: addv Table Generation: 31AU G2020 (09:18)
(Cutoff Date: 24AUG2020, Snapshot Date: 28AUG2020) Output File: (CDISC)/C4591001_IA_P1/adsl_l005_pd_p1
090177e194d7854f\Final\Final On: 07-Sep-2020 03:52 (GMT)
Page 1
FDA-CBER-2021-5683-0029230
16.2.2.1.1 Listing of Important Protocol Deviations – Phase 1 – BNT162b1 (100 μg )
Protocol
Deviation
Category Protocol Deviation Subcategory Number of
Subjects Subject
(Number of
Deviations if >1)
No subject me ets the reporting criteria.
PFIZER CONFIDENTIAL SDTM Creation: 28AUG2020 (16:27) Source Data: addv Table Generation: 19SEP2020 (10:20)
(Cutoff Date: 24AUG2020, Snapshot Date: 28AUG2020) Output File: ./nda3/C4591001_IA_P1_100/adsl_l005_pd_100_p1
090177e194fbc508\Final\Final On: 22-Sep-2020 14:24 (GMT)
Page 2
FDA-CBER-2021-5683-0029231